Novartis reported that its Phase 3 pelacarsen trial missed its primary endpoint, adding another high-profile failure to the cardiovascular outcomes landscape. The result further challenges an emerging class of heart medicines built around Lp(a) biology, even as companies attempt to separate biomarker lowering from hard clinical outcomes. For biotech and pharma observers, pelacarsen’s failure comes after the recent sequence of large cardiovascular trial setbacks referenced in the dataset, increasing scrutiny on whether Lp(a) reduction alone is sufficient for risk reduction. The immediate effect is likely to shift attention toward alternative mechanisms within lipid biology and toward designs that can better de-risk target engagement earlier in development.